Description: AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Home Page: www.an2therapeutics.com
ANTX Technical Analysis
1800 El Camino Real
Menlo Park,
CA
94027
United States
Phone:
650-331-9090
Officers
| Name | Title |
|---|---|
| Mr. Joseph S. Zakrzewski | Co-founder & Independent Chairman |
| Mr. Eric E. Easom | Co-founder, CEO, Pres & Director |
| Ms. Lucy O. Day CPA | CFO, Sec. & Treasurer |
| Dr. Paul Eckburg M.D. | Chief Medical Officer |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Sr. Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder & Head of Biology |
| Mr. Josh Eizen | Chief Legal Officer & Sec. |
| Dr. Sanjay Chanda Ph.D. | Chief Devel. Officer |
| Mr. Kevin Krause B.S., M.B.A. | Chief Strategy Officer |
| Ms. Jennifer Huber | Sr. VP of Regulatory Affairs & Quality |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8158 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-03-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |